821 related articles for article (PubMed ID: 16164572)
1. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
2. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes.
Lee KW; Lip GY; Blann AD
Circulation; 2004 Oct; 110(16):2355-60. PubMed ID: 15302795
[TBL] [Abstract][Full Text] [Related]
3. Plasma markers of angiogenesis in pregnancy induced hypertension.
Nadar SK; Karalis I; Al Yemeni E; Blann AD; Lip GY
Thromb Haemost; 2005 Nov; 94(5):1071-6. PubMed ID: 16363251
[TBL] [Abstract][Full Text] [Related]
4. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure.
Chong AY; Caine GJ; Freestone B; Blann AD; Lip GY
J Am Coll Cardiol; 2004 Feb; 43(3):423-8. PubMed ID: 15013125
[TBL] [Abstract][Full Text] [Related]
5. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY
Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Nadar S; Blann AD; Lip GY
Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
[TBL] [Abstract][Full Text] [Related]
7. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy.
Nadar SK; Blann AD; Lip GY
J Intern Med; 2004 Oct; 256(4):331-7. PubMed ID: 15367176
[TBL] [Abstract][Full Text] [Related]
8. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Nadar SK; Blann AD; Kamath S; Beevers DG; Lip GY
J Am Coll Cardiol; 2004 Jul; 44(2):415-22. PubMed ID: 15261941
[TBL] [Abstract][Full Text] [Related]
9. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Caine GJ; Stonelake PS; Lip GY; Blann AD
Cancer Lett; 2007 Apr; 248(1):131-6. PubMed ID: 16891056
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension.
Patel JV; Lim HS; Varughese GI; Hughes EA; Lip GY
Ann Med; 2008; 40(3):215-22. PubMed ID: 18382887
[TBL] [Abstract][Full Text] [Related]
11. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
12. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
Lee CY; Tien HF; Hu CY; Chou WC; Lin LI
Br J Cancer; 2007 Oct; 97(7):877-82. PubMed ID: 17848952
[TBL] [Abstract][Full Text] [Related]
13. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
Caine GJ; Ryan P; Lip GY; Blann AD
Cancer Lett; 2007 Jun; 251(2):296-301. PubMed ID: 17240049
[TBL] [Abstract][Full Text] [Related]
14. Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors.
Serefhanoglu S; Goker H; Buyukasik Y; Turgut M; Sayinalp N; Haznedaroglu IC; Aksu S; Akman U; Ozcebe OI
Ann Hematol; 2009 Jul; 88(7):667-71. PubMed ID: 19082594
[TBL] [Abstract][Full Text] [Related]
15. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
16. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment.
Mohan JS; Lip PL; Blann AD; Bareford D; Lip GY
Br J Ophthalmol; 2005 Jul; 89(7):815-9. PubMed ID: 15965157
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Jaumdally RJ; Goon PK; Varma C; Blann AD; Lip GY
J Intern Med; 2010 Apr; 267(4):385-93. PubMed ID: 19754853
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?
Freestone B; Chong AY; Lim HS; Blann A; Lip GY
Ann Med; 2005; 37(5):365-72. PubMed ID: 16179272
[TBL] [Abstract][Full Text] [Related]
20. Systemic and intracardiac vascular endothelial growth factor and angiopoietin-1 and -2 levels in coronary artery disease: effects of angioplasty.
Jaumdally RJ; Varma C; Blann AD; MacFadyen RJ; Lip GY
Ann Med; 2007; 39(4):298-305. PubMed ID: 17558601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
